Medicine
Praluent 150 mg/1 mL injection
Praluent 150 mg/1 mL injection is a prescription medicine containing Alirocumab for subcutaneous use, marketed by Regeneron Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to…
Key facts
- Active ingredient (INN)
- Alirocumab
- Brand
- Praluent
- Strength
- 150 mg/1 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 1 mL, 2 syringes of 1 mL and 2 more
- Marketing authorisation holder
- Regeneron Pharmaceuticals
- Manufacturers
- Regeneron PharmaceuticalsSanofi-Aventis
- Origin register
- US FDA, United States
- Storage
- Store in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not freeze. PRALUENT may be kept at room temperature up to 77°F (25°C) in the original carton for 30 days. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C10AX14 Alirocumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 24 July 2015
- Identifiers
- RxCUI 1659156, 1659161, 1659165 +5DailyMed set ID 446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4, 7bcfbac2-e8ac-4569-8edc-bcde3b1fd172NDC 0024-5902, 61755-021Application BLA125559
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, glass in 1 carton / 1 mL in 1 syringe, glass | 61755-021-01 | Regeneron Pharmaceuticals | 1 December 2020 |
| 2 syringe, glass in 1 carton / 1 mL in 1 syringe, glass | 61755-021-02 | Regeneron Pharmaceuticals | 1 December 2020 |
| 1 syringe, glass in 1 carton / 1 mL in 1 syringe, glass | 61755-021-04 | Regeneron Pharmaceuticals | 1 December 2020 |
| 1 syringe, glass in 1 carton / 1 mL in 1 syringe, glass | 0024-5902-00 | Sanofi-Aventis | 24 July 2015 |
| 1 syringe, glass in 1 carton / 1 mL in 1 syringe, glass | 0024-5902-01 | Sanofi-Aventis | 24 July 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Alirocumab
Clinical summary
Alirocumab is a PCSK9 inhibitor indicated to reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death, myocardial infarction, stroke, or unstable angina requiring hospitalization) in adults at increased risk for these events. MedsAcross supplies Alirocumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AlirocumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Praluent prescribing information (Regeneron Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Praluent: European public assessment report (EPAR) · European Medicines Agency
Need Praluent 150 mg/1 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.